Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and th
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers declined ... prices in 2008. However, the situation has stabilised afterwards, ... momentum now. , To date, the world annual production ... tonnes. No considerable growth was registered in the market ... 2012-2013, registering 11% growth as against the period of ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... leader in liquid photopurification, announced today that the ... approval for the continued trading of SurePure ("SURP") ... execution venture marketplace for entrepreneurial and development stage ... Markets Group introduced standards and eligibility requirements designed ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
Breaking Biology Technology:Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3
... 8 A study in the June issue of ... demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel ... fibrosis in patients with chronic hepatitis C (HCV), potentially ... care for staging fibrosis, in a particular subset of ...
... Interactive Agency Recognized for Excellence in Healthcare Marketing , ... Group , the premier strategic interactive marketing agency serving ... the 2009 Aster Awards with the ... healthcare marketing campaigns for DePuy Orthopaedics and AstraZeneca. ...
... , Amerinet Offering AccuVein,s AV300 Hand-Held Vein Illumination Device to ... June 8 AccuVein LLC today announced a three year ... world,s first hand-held, non-contact vein illumination device to its members. ... a patient,s skin revealing vein position to help the healthcare ...
Cached Biology Technology:Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 4Cadient Group Brings Home the Gold and Two Bronze Aster Awards 2AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... 2010) Calculations are fine, but seeing is believing. That,s ... who decided to put to the test calculations made more ... physicist Gustav Mie came up with an elegant set of ... spherical metal particle. The theory has been a touchstone ever ...
... Qatar WWF and TRAFFIC welcome a World Federation of ... use tiger bone or any other parts from endangered wildlife. ... Beijing and notes that some of the claimed medicinal benefits ... bones was removed from the traditional Chinese medicine (TCM) pharmacopeia ...
... 12, 2010 Keystone Symposia on Molecular and Cellular ... million, five-year MARC (Minority Access to Research Careers) Ancillary ... Medical Sciences of the National Institutes of Health (NIH). ... Keystone Symposia," the grant will fund the organization,s efforts ...
Cached Biology News:Look at Mie! 2Chinese medicine societies reject tiger bones ahead of CITES conference 2Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 2Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 3Keystone Symposia awarded $1.37 million, 5-year NIH grant to fund ongoing diversity efforts 4
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... Engineered with new technology incorporating the ... unsurpassed flexibility, the new Varian NMR ... spectrometer available today., ,The Varian NMR ... transmitter and receiver channel, providing pulse ...
Biology Products: